Get the Stockscreener App
0.00
100.00%
-0.0941
Palatin Technologies Inc. stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its drug development programs also include melanocortin receptor system program, such as PL-8177, a selective melanocortin receptor 1 agonist peptide for inflammatory bowel diseases; and PL-8331, a preclinical development candidate for treating ocular inflammation, as well as melanocortin receptor 4 peptides and orally-active small molecules to treat genetic metabolic and obesity disorders. In addition, the company develops natriuretic peptide receptor systems comprising PL3994, a natriuretic peptide receptor-A agonist, which has completed Phase I clinical study for the treatment of cardiovascular indications; and PL-5028, a dual natriuretic peptide receptor A and C agonist that is in preclinical development for cardiovascular diseases, such as reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
See More
Previous Close:
$0.0941
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$5.67M
Revenue:
$7.10M
Net Income/Loss:
$-31.59M
P/E Ratio:
0.00
EPS:
-2.61
Net Cash Flow:
$-26.75M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$2.13
Palatin Technologies Inc. Stock (PTN) Company Profile
Name
Palatin Technologies Inc.
Sector
Industry
Phone
609-495-2200
Address
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Compare PTN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.00 | 5.67M | 7.10M | -31.59M | -26.75M | -2.61 |
|
ONC
Beigene Ltd Adr
|
237.65 | 25.23B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.46 | 113.16B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.26 | 40.65M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.44 | 64.41B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.80 | 6.18B | 0 | -153.72M | -103.81M | -2.00 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-15 | Reiterated | Canaccord Genuity | Buy |
| Jan-12-15 | Reiterated | ROTH Capital | Buy |
| May-23-12 | Initiated | Noble Financial | Buy |
| Jan-23-07 | Initiated | Next Generation | Buy |
Palatin Technologies Inc. Stock (PTN) Latest News
Palatin Technologies, Inc. (AMEX:PTN) Q3 2025 Earnings Call Transcript - MSN
Palatin Technologies (NYSE:PTN) Coverage Initiated by Analysts at StockNews.com - Defense World
Moderate Dry Eye Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | mc2 therapeutics, Palatin Technologies, Novaliq - The Globe and Mail
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - The Malaysian Reserve
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Palatin Technologies Reports Q3 2025 Earnings and Updates - TipRanks
Palatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss By Investing.com - Investing.com Nigeria
Earnings call transcript: Palatin’s Q3 FY2025 shows narrower loss - Investing.com Australia
Palatin Technologies Q1 Net Loss Narrows On Lower Expenses - Nasdaq
Palatin Technologies (PTN) to Release Quarterly Earnings on Wednesday - Defense World
Palatin Technologies director Robert DeVeer buys $10,180 in stock By Investing.com - Investing.com Nigeria
Palatin Technologies director Robert DeVeer buys $10,180 in stock - Investing.com
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com India
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin Technologies Announces Closing of Reduced Public Offerin - GuruFocus
Two new option listings and two option delistings on May 9th - TipRanks
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering - Morningstar
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com Canada
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Australia
Palatin Technologies sets terms for $23 million offering By Investing.com - Investing.com South Africa
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa
Palatin Prices $11.5 Mln Public Offering - Nasdaq
Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq
Palatin (PTN) Aims to Address Delisting Concerns with Public Off - GuruFocus
Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com
Palatin Expects $11.5 Million Financing to Cure NYSE American De - GuruFocus
Palatin Expects $11.5 Million Financing - citybiz
Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - GuruFocus
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering | PTN Stock News - GuruFocus
Palatin Technologies sets terms for $23 million offering - Investing.com
Palatin Technologies Inc. Stock (PTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.48%
1.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):